ANRO
Alto Neuroscience·NYSE
--
--(--)
--
--(--)
ANRO fundamentals
During Q4 2025, Alto Neuroscience (ANRO) reported revenue of --, a YoY change of 0.00%. Net income was -16.18M, a YoY change of -6.45%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 8.06M -- | 7.20M -- | 9.13M -- | 9.72M -- | 11.77M +45.97% | 14.39M +99.78% | 18.34M +101.00% | 18.89M +94.34% | 17.00M +44.47% | 15.68M +8.97% | 18.68M +1.86% | 14.95M -20.84% | 17.05M +0.34% | 66.36M -- |
Selling, General and Administrative Expenses | 1.74M -- | 1.59M -- | 2.05M -- | 1.75M -- | 2.12M +22.24% | 4.43M +178.52% | 5.16M +151.19% | 5.83M +232.72% | 6.20M +192.04% | 5.70M +28.60% | 5.56M +7.78% | 4.43M -24.03% | 5.06M -18.36% | 20.75M -- |
General and Administrative Expenses | 1.74M -- | -- -- | -- -- | 1.75M -- | 2.12M +22.24% | 4.43M -- | 5.16M -- | 5.83M +232.72% | 6.20M +192.04% | 5.70M +28.60% | 5.56M +7.78% | 4.43M -24.03% | 5.06M -18.36% | 20.75M -- |
Research and Development Expenses | 6.32M -- | 5.61M -- | 7.07M -- | 7.97M -- | 9.64M +52.48% | 9.95M +77.43% | 13.18M +86.43% | 13.06M +63.93% | 10.80M +12.00% | 9.97M +0.22% | 13.12M -0.46% | 10.53M -19.41% | 12.00M +11.07% | 45.62M -- |
Operating Income | -8.06M -- | -7.20M -- | -9.13M -- | -9.72M -- | -11.77M -45.97% | -14.39M -99.78% | -18.34M -101.00% | -18.89M -94.34% | -17.00M -44.47% | -15.68M -8.97% | -18.68M -1.86% | -14.95M +20.84% | -17.05M -0.34% | -66.36M -- |
Non-Operating Income (Loss) | 408.00K -- | -83.00K -- | 462.00K -- | 577.00K -- | 548.00K +34.31% | 969.00K +1267.47% | 2.31M +400.22% | 2.10M +264.47% | 1.80M +227.74% | 507.00K -47.68% | 976.00K -57.77% | 770.00K -63.39% | 873.00K -51.39% | 3.13M -- |
Gain (Loss) on Change in Fair Value | 265.00K -- | -- -- | -- -- | 226.00K -- | -359.00K -235.47% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Non-Operating Income (Loss) | 31.00K -- | 11.00K -- | 122.00K -- | -- -- | 525.00K +1593.55% | -243.00K -2309.09% | 0 -100.00% | -48.00K -- | -6.00K -101.14% | -722.00K -197.12% | -61.00K -- | -112.00K -133.33% | -113.00K -1783.33% | -1.01M -- |
Net Interest Expense | -112.00K -- | 94.00K -- | -340.00K -- | -351.00K -- | -382.00K -241.07% | -1.21M -1389.36% | -2.31M -579.71% | -2.15M -512.82% | -1.80M -371.73% | -1.23M -1.40% | -1.04M +55.13% | -882.00K +59.00% | -986.00K +45.28% | -4.13M -- |
Interest Expense | 0 -- | 324.00K -- | 327.00K -- | 363.00K -- | 356.00K -- | 346.00K +6.79% | 347.00K +6.12% | 349.00K -3.86% | 333.00K -6.46% | 598.00K +72.83% | 646.00K +86.17% | 650.00K +86.25% | 575.00K +72.67% | 2.47M -- |
Interest Income | 112.00K -- | 230.00K -- | 667.00K -- | 714.00K -- | 738.00K +558.93% | 1.56M +577.39% | 2.66M +298.50% | 2.50M +250.14% | 2.13M +189.30% | 1.83M +17.27% | 1.68M -36.68% | 1.53M -38.72% | 1.56M -26.89% | 6.60M -- |
Pretax Income From Continuing Operations | -7.65M -- | -7.28M -- | -8.66M -- | -9.14M -- | -11.22M -46.59% | -13.42M -84.20% | -16.03M -85.04% | -16.78M -83.60% | -15.20M -35.52% | -15.17M -13.06% | -17.71M -10.46% | -14.18M +15.50% | -16.18M -6.45% | -63.24M -- |
Income Tax Expense | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -7.65M -- | -7.28M -- | -8.66M -- | -9.14M -- | -11.22M -46.59% | -13.42M -84.20% | -16.03M -85.04% | -16.78M -83.60% | -15.20M -35.52% | -15.17M -13.06% | -17.71M -10.46% | -14.18M +15.50% | -16.18M -6.45% | -63.24M -- |
Net Income Attributable to Owners of the Company | -7.65M -- | -7.28M -- | -8.66M -- | -9.14M -- | -11.22M -46.59% | -13.42M -84.20% | -16.03M -85.04% | -16.78M -83.60% | -15.20M -35.52% | -15.17M -13.06% | -17.71M -10.46% | -14.18M +15.50% | -16.18M -6.45% | -63.24M -- |
Net Income Attributable to Common Stockholders | -7.65M -- | -7.28M -- | -8.66M -- | -9.14M -- | -11.22M -46.59% | -13.42M -84.20% | -16.03M -85.04% | -16.78M -83.60% | -15.20M -35.52% | -15.17M -13.06% | -17.71M -10.46% | -14.18M +15.50% | -16.18M -6.45% | -63.24M -- |
Other Comprehensive Income | 5.00K -- | -19.00K -- | -11.00K -- | -10.00K -- | 7.00K +40.00% | -5.00K +73.68% | -5.00K +54.55% | -6.00K +40.00% | -6.00K -185.71% | 115.00K +2400.00% | 17.00K +440.00% | -17.00K -183.33% | 8.00K +233.33% | 123.00K -- |
Total Comprehensive Income | -7.65M -- | -7.30M -- | -8.67M -- | -9.15M -- | -11.21M -46.59% | -13.42M -83.79% | -16.04M -84.86% | -16.79M -83.47% | -15.21M -35.66% | -15.05M -12.16% | -17.69M -10.31% | -14.20M +15.43% | -16.17M -6.36% | -63.12M -- |
Total Comprehensive Income Attributable to Owners of the Company | -7.65M -- | -7.30M -- | -8.67M -- | -9.15M -- | -11.21M -46.59% | -13.42M -83.79% | -16.04M -84.86% | -16.79M -83.47% | -15.21M -35.66% | -15.05M -12.16% | -17.69M -10.31% | -14.20M +15.43% | -16.17M -6.36% | -63.12M -- |
Basic EPS | -- -- | -1.97 -- | -2.33 -- | -2.44 -- | -- -- | -0.76 +61.42% | -0.6 +74.25% | -0.62 +74.59% | -0.56 -- | -0.56 +26.32% | -0.65 -8.33% | -0.52 +16.13% | -0.51 +8.93% | -2.24 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -2.44 -- | -- -- | -0.76 -- | -0.6 -- | -0.62 +74.59% | -- -- | -0.56 +26.32% | -0.65 -8.33% | -0.52 +16.13% | -- -- | -- -- |
Diluted EPS | -- -- | -1.97 -- | -2.33 -- | -2.44 -- | -- -- | -0.76 +61.42% | -0.6 +74.25% | -0.62 +74.59% | -- -- | -0.56 +26.32% | -0.65 -8.33% | -0.52 +16.13% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -2.44 -- | -- -- | -0.76 -- | -0.6 -- | -0.62 +74.59% | -- -- | -0.56 +26.32% | -0.65 -8.33% | -0.52 +16.13% | -- -- | -- -- |
You can ask Aime
What is the market's earnings forecast for Alto Neuroscience next quarter?What factors drove the changes in Alto Neuroscience's revenue and profit?Did Alto Neuroscience beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Alto Neuroscience year over year?What is Alto Neuroscience's gross profit margin?What guidance did Alto Neuroscience's management provide for the next earnings period?What were the key takeaways from Alto Neuroscience’s earnings call?What is Alto Neuroscience's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
